**This Longevity Molecule Extends Primate Lifespan by 15% | Adam Salmon (via Modern Healthspan)**
2 Likes
I. Executive Summary
In this technical interview, Dr. Adam Salmon, Associate Director of the Barshop Institute for Longevity and Aging Studies at UT Health San Antonio, presents pre-publication survival and healthspan findings from the first long-term longevity trial of rapamycin in a non-human primate, the common marmoset (Callithrix jacchus). Addressing the translational chasm between inbred laboratory rodents and humans, Salmon outlines why outbred marmosets—which live an average of seven to nine years and spontaneously develop human-relevant cardiovascular, renal, periodontal, and osteoarthritic pathologies—serve as an indispensable bridge prior to human gerotherapeutic deployment.
Initiated in 2016, the controlled cohort enrolled nearly 70 middle-aged marmosets (approximately seven years old,corresponding to mid-50s to early-60s in humans) randomized to daily oral rapamycin (approximately 1 mg/kg/day) or control. With nearly complete natural mortality across the cohort, chronic rapamycin extended average lifespan by 10% to 15%—an effect size matching early murine studies and projecting to roughly a decade of human life expectancy if translated linearly. Unlike National Institute on Aging Interventions Testing Program (ITP) mouse cohorts, marmosets exhibited no pronounced sex-specific survival divergence, reflecting minimal baseline sexual dimorphism in this species.
Clinically, rapamycin did not augment baseline physiological capacity above youthful norms but attenuated age-related functional decline, preserving renal metrics and delaying dental caries and periodontal disease. Crucially, despite high-dose daily administration, marmosets did not develop the persistent hyperglycemia, elevated HbA1c, or impaired oral glucose tolerance reliably induced in mice—a divergence Salmon attributes to murine liver mass proportions (3% to 5% of body weight in mice versus under 1% in humans) amplifying hepatic mTORC2-mediated gluconeogenic dysfunction.However, post-hoc histopathological evaluation conducted with collaborators at the University of Wisconsin-Madison uncovered a sexually dimorphic adverse signal: female marmosets receiving chronic daily rapamycin developed significantly exacerbated knee osteoarthritis, potentially linked to chondrocyte mTORC2 suppression. Salmon concludes that while rapamycin validates mTOR pathway conservation in primates, human clinical translation favors intermittent dosing regimens or next-generation mTORC1-selective inhibitors to capture geroprotective benefits while mitigating mTORC2-driven metabolic and musculoskeletal liabilities.
II. Insight Bullets
-
Inbred laboratory mice fail to spontaneously develop many human age-related diseases, creating a major translational gap when validating gerotherapeutic interventions.
-
Common marmosets (Callithrix jacchus) provide a practical non-human primate aging model due to their seven-to-nine-year average lifespan compared to the 40-plus-year lifespan of rhesus macaques.
-
Outbred marmoset colonies naturally develop human-like age-related cardiovascular disease, chronic kidney disease, periodontal disease, and osteoarthritis.
-
Marmosets do not naturally develop classic Alzheimer’s disease neuropathology, limiting their utility as a standalone model for human amyloid-tau neurodegeneration.
-
The Barshop Institute marmoset study enrolled nearly 70 middle-aged animals at roughly seven years of age,equivalent to humans in their mid-50s to early 60s.
-
Treated marmosets received daily oral rapamycin at approximately 1 mg/kg/day, a high dose modeled on foundational murine lifespan protocols rather than human intermittent regimens.
-
Chronic daily rapamycin extended mean marmoset lifespan by 10% to 15%, with full necropsy and cause-of-death pathology analyses targeted for publication by early 2027 (Source unverified in live search).
-
Unlike mouse cohorts in the Interventions Testing Program (ITP), marmosets showed no strong sex-specific difference in rapamycin-induced survival, consistent with their minimal sexual dimorphism.
-
Because marmosets exhibit substantial inter-individual survival variation similar to humans, baseline health history prior to treatment initiation strongly influences longevity outcomes.
-
Rapamycin treatment in marmosets preserved longitudinal kidney function by delaying functional decline rather than enhancing baseline renal performance above normal levels.
-
Collaborative dental pathology research at UT Health San Antonio demonstrated that rapamycin significantly delays dental cavities and periodontal disease progression in aging marmosets (Source unverified in live search).
-
Contrary to consistent murine findings, daily high-dose rapamycin did not induce persistent elevations in fasting glucose, HbA1c, or oral glucose intolerance in marmosets.
-
Species differences in relative liver mass—comprising 3% to 5% of body weight in mice versus less than 1% in humans—likely explain why mice suffer severe hepatic mTORC2-driven hyperglycemia under chronic rapamycin (Lamming et al., 2012; Source unverified in live search).
-
While organ transplant patients taking chronic high-dose rapamycin alongside immunosuppressive cocktails show elevated new-onset diabetes risk, metabolic risk in healthy humans remains unconfirmed.
-
Post-hoc joint pathology analysis conducted with Adam Konopka at the University of Wisconsin-Madison revealed that female marmosets on daily rapamycin experienced worsened knee osteoarthritis (Source unverified in live search).
-
Rapamycin-induced adverse effects, including oral aphthous stomatitis and transient glucose dysregulation, resolve rapidly within days to a week following drug discontinuation.
-
Intermittent weekly or biweekly rapamycin dosing in humans is hypothesized to preserve mTORC1-mediated autophagy benefits while allowing periodic mTORC1 recovery and preventing chronic mTORC2 inhibition.
-
Prior transgenic mouse research conducted by Salmon and Arlan Richardson demonstrated that global antioxidant overexpression fails to extend baseline lifespan, though mitigating oxidative stress protects metabolic health during high-fat diet challenges (Source unverified in live search).
-
Current research at the Barshop Institute focuses on mitochondrial dynamics and bioenergetic resilience as primary drivers of age-related immune and physiological decline.
-
Development of selective mTORC1 inhibitors that avoid off-target mTORC2 suppression represents a key pharmaceutical strategy to capture longevity benefits without metabolic or chondrocyte toxicity.
-
Artificial intelligence models cannot currently replace physiological non-human primate aging studies due to the multi-system, individualized complexity of mammalian senescence.
III. Adversarial Claims & Evidence Table
| Claim from Video | Speaker’s Evidence | Scientific Reality (Current Data) | Evidence Grade (A-E) | Verdict |
|---|---|---|---|---|
| Daily oral rapamycin (1 mg/kg/day) initiated in middle-aged marmosets extends average lifespan by 10% to 15%. | Speaker’s unpublished/ongoing longitudinal survival cohort at UT Health San Antonio (n ~ 70 marmosets; necropsy analysis pending for 2026/2027 publication). | Source unverified in live search. Represents a major milestone as the first long-term survival signal for a gerotherapeutic drug in a non-human primate, corroborating NIA ITP mouse survival gains (~9%–26% across sexes). Translational Gap: High daily dosing (1 mg/kg/day) exceeds human off-label intermittent regimens by an order of magnitude, and full peer-reviewed survival curves and cause-of-death pathology remain unpublished. | Level D (Pre-clinical Non-Human Primate Study - Translational Gap) | Plausible |
| Rapamycin delays periodontal disease and dental caries progression in aging marmosets. | Speaker’s 2026 collaborative publication with UT Health San Antonio dental researchers analyzing longitudinal oral exams in the marmoset cohort. | Source unverified in live search. Consistent with established murine geroscience studies (e.g., An et al., eLife 2020) showing short-term rapamycin rejuvenates aged periodontal bone, reduces gingival inflammation, and shifts the oral microbiome toward a youthful composition. Human clinical RCTs for periodontal endpoints are currently underway. | Level D (Pre-clinical Non-Human Primate Study - Translational Gap) | Strong Support |
| Chronic daily rapamycin exacerbates knee osteoarthritis pathology specifically in female marmosets. | Post-hoc histopathological knee joint analysis of the marmoset cohort published with Adam Konopka (University of Wisconsin). | Source unverified in live search. Mechanistically plausible given that articular cartilage homeostasis relies on balanced mTORC1/mTORC2 signaling; while acute intra-articular rapamycin can protect against post-traumatic osteoarthritis in mice, chronic systemic mTORC2 disruption impairs chondrocyte survival and matrix synthesis. Highlights a critical sex-specific safety signal missed in quadrupedal mouse studies. | Level D (Pre-clinical Non-Human Primate Study - Translational Gap) | Safety Warning |
| Chronic rapamycin induces glucose intolerance via hepatic mTORC2 inhibition in mice, whereas marmosets did not develop persistent hyperglycemia or elevated HbA1c. | Speaker’s 2012 co-authored mechanistic paper (Lamming et al., Science) and longitudinal OGTT/HbA1c monitoring in the marmoset cohort. | Source unverified in live search. Well-established in rodent physiology: chronic rapamycin disrupts mTORC2 assembly, impairing insulin-mediated suppression of hepatic gluconeogenesis. In human organ transplant recipients, sirolimus increases new-onset diabetes incidence, whereas small short-term human trials of low-dose intermittent everolimus/rapamycin in healthy older adults (e.g., Mannick et al., Sci Transl Med 2014; Kraig et al., Exp Gerontol 2018) have generally shown minimal or transient glycemic perturbation. | Level B (Human Clinical Biomarker Trials) / Level D (Primate & Mouse Data) | Plausible |
| Intermittent rapamycin dosing preserves lifespan extension while minimizing metabolic and immunosuppressive side effects compared to daily dosing. | Cited NIA Interventions Testing Program (ITP) intermittent dosing mouse data and clinical trial designs using weekly dosing. | Source unverified in live search. Supported by rodent studies (e.g., Arriola Apelo et al., Aging Cell 2016) showing intermittent rapamycin (once every 5 days) extends female mouse lifespan while sparing glucose tolerance and immune function, alongside human immunosenescence RCTs (Mannick et al., 2014/2018) showing weekly low-dose RAD001 enhances influenza vaccine response without severe adverse events. | Level B (Human Immunosenescence RCTs) / Level D (Mouse Lifespan) | Strong Support |
| Genetic overexpression of endogenous antioxidant enzymes fails to extend baseline mammalian lifespan, though it mitigates high-fat diet metabolic dysfunction. | Speaker’s postdoctoral research with Arlan Richardson at the Barshop Institute across multiple transgenic mouse lines. | Source unverified in live search. Widely replicated across biogerontology literature (e.g., Pérez et al., Biochim Biophys Acta 2009), refuting the simple free radical theory of aging in normoxic mammals while confirming that mitochondrial reactive oxygen species (ROS) modulation preserves insulin sensitivity under nutrient excess. | Level D (Pre-clinical Transgenic Mouse Studies - Translational Gap) | Strong Support |
IV. Actionable Protocol (Prioritized)
High Confidence Tier (Level A/B Evidence)
| Domain | Clinical Action | Dosing / Target | Primary Endpoint |
|---|---|---|---|
| Physiological mTORC1 Modulation & Metabolic Resilience | Utilize structured caloric moderation and progressive aerobic plus resistance exercise to cyclically regulate endogenous mTORC1, AMPK, and mitochondrial biogenesis without pharmacologic mTORC2 toxicity. | 150 to 300 minutes/week Zone 2 aerobic training plus 2 to 3 sessions/week resistance training; avoid chronic caloric surplus. | Preservation of insulin sensitivity, mitochondrial oxidative capacity, and age-adjusted VO2 max. |
| Periodontal & Oral Health Preservation | Maintain rigorous mechanical plaque control and biannual professional periodontal debridement to prevent chronic oral inflammation and alveolar bone loss. | Twice-daily brushing, interdental cleaning, and 6-month dental prophylaxis targeting probing depths less than 3 mm. | Reduction in systemic inflammatory burden (hs-CRP) and prevention of age-related periodontitis. |
| Osteoarthritis & Joint Integrity Protection | Prioritize quadriceps/hamstring strength, neuromuscular stability, and body-mass optimization to protect articular cartilage against age-related degeneration. | 2 to 3 sessions/week lower-extremity closed-chain strength training; maintain BMI within 18.5 to 24.9 kg/m2. | Preservation of knee joint space width, chondrocyte homeostasis, and functional mobility. |
Experimental Tier (Level C/D Evidence - High Safety Margin)
-
Intermittent Low-Dose Rapamycin (Sirolimus) Protocol: For adults electing physician-supervised off-label gerotherapeutic use, intermittent dosing (typically 3 mg to 6 mg orally once weekly, rather than daily administration) aims to pulse mTORC1 inhibition while allowing trough clearance to prevent chronic mTORC2 disassembly; requires baseline and quarterly monitoring of fasting glucose, HbA1c, fasting insulin, complete blood count (CBC), ApoB/lipid panel, and renal function.
-
Oral Glucose Tolerance Test (OGTT) Surveillance Over Fasting Glucose Alone: Because rapamycin-induced hepatic/peripheral insulin resistance may manifest initially as postprandial glucose excursion rather than elevated fasting glucose, perform a 2-hour 75 g OGTT (or postprandial capillary glucose check) 4 to 8 weeks after initiating therapy to verify intact metabolic resilience.
-
Proactive Sex-Specific Musculoskeletal Monitoring: Given the newly identified female-specific knee osteoarthritis signal in chronically treated marmosets, post-menopausal women or individuals with pre-existing cartilage wear utilizing mTOR inhibitors should monitor joint symptoms closely and pair therapy with heavy resistance training and collagen/biomechanical joint support.
2 Likes
Fantastic!! I will take 15 extra healthy years.
Can’t wait to see this:
- Chronic daily rapamycin extended mean marmoset lifespan by 10% to 15%, with full necropsy and cause-of-death pathology analyses targeted for publication by early 2027 (Source unverified in live search).
2 Likes
There were some interesting tidbits in this interview, which is why I posted it. Unfortunately, the interviewer is not the sharpest knife in the drawer, and doesn’t pursue the more interesting threads. For example, he suffers from the common “naturalistic fallacy” wherein he thinks polypharmacy is a negative in principle, because more than one drug is negative due to… something or other. When discussing glucose perturbances from rapamycin, Salmon mentioned that you could use diabetes drugs to ameliorate the glucose issue with rapamycin, at which point, instead of pursuing this interesting thread, the interviewer immediately shut it down as something undesirable and “we don’t want to promote that”, even though Salmon said that would be his preference. Clearly the interviewer doesn’t seem aware of the fact that diabetic drugs like acarbose and canagliflozin were shown in the ITP to actually synergize with rapamycin, so polypharmacy is not only the obvious way to ameliorate negative side effects of rapamycin but are actually desirable in providing a boost to longevity in combination… this despite Salmon mentioning the ITP and canagliflozin earlier. Nothing like ignorance, prejudice and limited intellectual abilities, which this host exhibits in spades. Overall, while there were interesting parts, it was a missed opportunity by the host (who doesn’t seem very robust himself, fwiw… I was half expecting him to keel over halfway through the interview).
5 Likes